Plain-English translation of NCT05287568 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether two medications — and — work better together to treat acute myeloid leukemia (a serious blood cancer). Researchers will first find the safest and most effective dose by gradually increasing the amount of while pairing it with . Then they will test this combination in a larger group of patients whose disease has returned or stopped responding to previous treatment.
Acute myeloid leukemia is a life-threatening cancer, and some patients cannot handle the most intensive standard treatments because of age, other health problems, or how sick they are. This trial explores whether this medication combination might be a gentler but still effective option for these patients.
You likely qualify if…
You likely don't qualify if…
You will be admitted to the hospital for your first treatment cycle. You will take as a pill by mouth for 14 days, and receive (which starts at 100 mg and increases to 400 mg over three days, then continues daily) for 28 days. During this time you will have blood tests and bone marrow biopsies to check how well the treatment is working and monitor for side effects. After the first cycle, you may continue treatment as an outpatient if things go well, with ongoing visits for blood work and bone marrow checks to track your response.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Colorado, Denver
Collaborators
Bristol-Myers Squibb
Enrollment target
~35 participants
Started
December 2022
Primary completion
March 2027
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Derek Schatz
University of Colorado, Denver
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.